EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

The Synergistic Effect of PARP Inhibitors and Irinotecan in Small Cell Lung Cancer Cells

Songji Oh, Soyeon Kim, Bhumsuk Keam, Jeonghwan Youk, Tae Min Kim, Dong-Wan Kim, Miso Kim

Cancer Research and Treatment · 15.10.2025 · 57 (4) · 1040-1050

DOI: 10.4143/crt.2024.728 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Research and Treatment, erschienen am 15.10.2025. Verfasst von Songji Oh und 6 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Research Institute, Seoul National University, Seoul, Korea. Hauptthemen laut MEDLINE: Irinotecan, Poly(ADP-ribose) Polymerase Inhibitors, Small Cell Lung Carcinoma, Lung Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: National Research Foundation of Korea, Ministry of Science and ICT, Alpha Biopharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This study focused on combining irinotecan with poly(ADP-ribose) polymerase (PARP) inhibitors to explore the potential for novel combination therapeutics in small cell lung cancer (SCLC).Materials and Methods We selected 10 different SCLC cell lines with diverse mutational backgrounds in DNA damage response (DDR) pathway genes to evaluate the efficacy of the combination of three PARP inhibitors and irinotecan. After the cells were exposed to the drugs for 7 days, cell viability was measured, and a combination index was calculated. Apoptotic signaling was assessed via western blot, and DNA damage was evaluated using an alkaline comet assay.

Results

We assessed the synergistic effects of PARP inhibitors and irinotecan in in vitro SCLC models, which revealed increased sensitivity, particularly in cells harboring BRCA mutations. However, even in cells lacking mutations in DDR pathway genes, the combination of the two drugs exhibited a synergistic effect. When treated with 50 nM irinotecan, the IC50 fold changes for PARP inhibitors were as follows: olaparib, 1,649±4,049; talazoparib, 25±34.21; venadaparib, 336±596.01. This combination enhanced apoptosis signaling and increased p-chk1 and p-p53 protein levels. Additionally, the treatment of PARP inhibitor with irinotecan increased DNA damage, as visualized by the alkaline comet assay.

Conclusion

This study provides preclinical evidence of the potential clinical benefits of combining irinotecan with PARP inhibitors in SCLC. Further clinical investigations are warranted to validate these findings for the development of more effective and personalized therapeutic strategies for SCLC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IrinotecanPoly(ADP-ribose) Polymerase InhibitorsSmall Cell Lung CarcinomaLung NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansDrug SynergismCell Line, TumorApoptosisDNA DamageCell SurvivalPhthalazines

Stichwörter der Autor:innen

IrinotecanPoly(ADP-ribose) polymerase inhibitorsSmall cell lung carcinoma

Substanzen

IrinotecanPoly(ADP-ribose) Polymerase InhibitorsPhthalazines

Autor:innen und Institutionen

  • Cancer Research Institute, Seoul National University, Seoul, Korea.
  • Integrated Major in Innovative Medical Science, Seoul National University College of Medicine, Seoul, Korea.
  • Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.

Förderung

  • National Research Foundation of Korea
  • Ministry of Science and ICT
  • Alpha Biopharma
  • Amgen
  • Astrazeneca/Medimmune
  • Boehringer-Ingelheim
  • Bridge BioTherapeutics
  • Chong Kun Dang

Zitieren

APA

Oh, S., Kim, S., Keam, B., Youk, J., Kim, T. M., Kim, D. W., & Kim, M. (2025). The Synergistic Effect of PARP Inhibitors and Irinotecan in Small Cell Lung Cancer Cells. Cancer Research and Treatment, 57(4), 1040-1050. https://doi.org/10.4143/crt.2024.728

Vancouver

Oh S, Kim S, Keam B, Youk J, Kim TM, Kim DW, et al. The Synergistic Effect of PARP Inhibitors and Irinotecan in Small Cell Lung Cancer Cells. Cancer Research and Treatment. 2025;57(4):1040-1050. doi:10.4143/crt.2024.728

BibTeX
@article{Oh2025,
  author = {Oh, Songji and Kim, Soyeon and Keam, Bhumsuk and Youk, Jeonghwan and Kim, Tae Min and Kim, Dong-Wan and Kim, Miso},
  title = {The Synergistic Effect of PARP Inhibitors and Irinotecan in Small Cell Lung Cancer Cells},
  journal = {Cancer Research and Treatment},
  year = {2025},
  volume = {57},
  number = {4},
  pages = {1040--1050},
  doi = {10.4143/crt.2024.728}
}
Kostenlos starten →